RenovoRx, Inc.
RNXT evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for RNXT—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · RNXT
RenovoRx, Inc. (RNXT) is a biopharmaceutical company developing a novel oncology drug-device combination product, IAG (intra-arterial gemcitabine via RenovoCath), for locally advanced pancreatic cancer, with a Phase III trial ongoing and a commercial device platform generating limited revenue.
Key risk: Cash runway uncertainty
BioSniper Score
Based on 6 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 2 pipeline candidates · 2 clinical trials · 1 catalyst for RenovoRx, Inc..
RenovoRx, Inc. (RNXT) is a biopharmaceutical company developing a novel oncology drug-device combination product, IAG (intra-arterial gemcitabine via RenovoCath), for locally advanced pancreatic cancer, with a Phase III trial ongoing and a commercial device platform generating limited revenue.
- Lead product candidate is IAG, a drug-device combination using the FDA-cleared RenovoCath catheter for intra-arterial gemcitabine infusion in locally advanced pancreatic cancer [sec_mda · as of 2024-11-13].
- Cash and cash equivalents were $9.5 million as of June 30, 2026 [sec_mda · as of 2026-08-13].
- Net loss of $6.4 million for the six months ended June 30, 2026, with an accumulated deficit of $67.8 million [sec_mda · as of 2026-08-13].
- Total revenue of $0.9 million for the six months ended June 30, 2026, primarily from RenovoCath commercial sales [latest reported financials].
- Phase III TIGeR-PaC trial is ongoing, comparing targeted intra-arterial gemcitabine versus continuation of IV gemcitabine plus nab-paclitaxel [sec_mda · as of 2024-11-13].
What works
- RenovoCath is already FDA-cleared for temporary vessel occlusion, providing a commercial revenue stream and a validated platform for IAG delivery [sec_mda · as of 2024-11-13].
- IAG is being evaluated in a Phase III randomized trial (TIGeR-PaC) for locally advanced pancreatic cancer, a high-need indication with limited treatment options [sec_mda · as of 2024-11-13].
- The company has a clear regulatory pathway via FDA's 21 CFR 312 IND pathway for the drug-device combination [sec_mda · as of 2024-11-13].
What to weigh
- Cash position of $9.5 million as of June 30, 2026, is limited relative to ongoing losses and the need to fund Phase III development and potential commercialization [sec_mda · as of 2026-08-13].
- The company has an accumulated deficit of $67.8 million and expects to continue incurring significant operating losses and negative cash flows [sec_mda · as of 2026-08-13].
- No revenue from IAG is expected until regulatory approval and commercial launch, which may be years away and is uncertain [sec_mda · as of 2026-08-13].
- The company may need additional financing to continue operations, and failure to obtain it could lead to delays or discontinuation of development [sec_mda · as of 2026-08-13].
From the filings
Quoted directly from source documents.
Cash and cash equivalents were $9.5 million as of June 30, 2026.
“As of June 30, 2026, the Company had cash and cash equivalents of approximately $ 9.5 million .”
SEC MD&A · August 13, 2026
Net loss of $6.4 million for the six months ended June 30, 2026.
“For the six months ended June 30, 2026, the Company reported a net loss of $ 6.4 million”
SEC MD&A · August 13, 2026
Accumulated deficit of $67.8 million as of June 30, 2026.
“an accumulated deficit of $ 67.8 million”
SEC MD&A · August 13, 2026
IAG is being evaluated in a Phase III trial for locally advanced pancreatic cancer.
“The intra-arterial infusion of the chemotherapy gemcitabine utilizing RenovoCath is currently being evaluated for the treatment of locally advanced pancreatic cancer ("LAPC") by the Center for Drug Evaluation and Research (the drug division of FDA) in our ongoing Phase III TIGeR-PaC randomized multi-cente”
SEC MD&A · November 13, 2024
Catalyst timeline
- 2027-09-01 · Phase3_Topline — Topline results from the Phase III TIGeR-PaC trial comparing targeted intra-arterial gemcitabine vs. continuation of IV gemcitabine plus nab-paclitaxel.
Risks & what to watch (4)›
Key risks
- Cash runway uncertainty — Only $9.5M cash as of June 30, 2026, with ongoing losses; may need additional financing [sec_mda · as of 2026-08-13].
- Clinical trial risk — Phase III TIGeR-PaC trial may fail to meet endpoints, delaying or preventing IAG approval [sec_mda · as of 2024-11-13].
- Regulatory approval risk — IAG requires FDA approval; no guarantee of success or timeline [sec_mda · as of 2026-08-13].
- Going concern risk — Company has incurred significant losses and negative cash flows; may not achieve positive cash flows in near future [sec_mda · as of 2026-08-13].
What to watch
- Phase III TIGeR-PaC topline data expected around September 2027 [upcoming catalysts].
- Cash burn rate and any financing activities to extend runway [sec_mda · as of 2026-08-13].
- RenovoCath commercial sales growth trajectory [sec_mda · as of 2026-08-13].
- Regulatory updates from FDA regarding IAG's IND or potential approval pathway [sec_mda · as of 2024-11-13].
Sources: SEC MD&A · Generated August 27, 2026 · How we verify sources →
Run RenovoRx, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available RenovoRx, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 6 of 6 signals · derived from public data
10.3 months
D/E 0.28 · 0% dilution
Lead: Phase 3
2 candidates
1 upcoming, next in ~367d
4 buys · 0 sells (180d)
Runway
Catalysts
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
27
Total value held
$4.3M
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 2,894,354 | $2.9M |
| geode capital management, llc | 381,723 | $386K |
| citadel advisors llc | 232,684 | $235K |
| vanguard fiduciary trust co | 157,902 | $159K |
| northwestern mutual wealth management co | 99,460 | $100K |
| nixon peabody trust co | 97,165 | $98K |
| caprock group, llc | 63,940 | $65K |
| northern trust corp | 42,161 | $43K |
| kestra advisory services, llc | 35,520 | $36K |
| xtx topco ltd | 30,511 | $31K |
Showing top 10 of 27 institutional holders of RenovoRx, Inc.. Open the full 13F history after sign-in.
Short Interest
as of May 22, 2026- % of float
- 1.2%
- Days to cover
- 1.6
- Shares short
- 505,892
- Daily short volume (May 20, 2026)
- 34.5%
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
RNXT short interestGovernance
Frequently asked questions
What is the AI investment thesis for RenovoRx, Inc.?
RenovoRx, Inc. (RNXT) is a biopharmaceutical company developing a novel oncology drug-device combination product, IAG (intra-arterial gemcitabine via RenovoCath), for locally advanced pancreatic cancer, with a Phase III trial ongoing and a commercial device platform generating limited revenue.
What is RenovoRx, Inc.'s lead drug candidate?
RenovoRx, Inc.'s most advanced tracked candidate is iag (Phase 3) for locally advanced pancreatic cancer.
What is RenovoRx, Inc.'s next catalyst?
RenovoRx, Inc.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: Targeted Intra-arterial Gemcitabine vs. Continuation of IV Gemcitabine Plus Nab-Paclitaxel Following" — expected September 1, 2027.
Who is the CEO of RenovoRx, Inc.?
Mr. Shaun R. Bagai is the chief executive officer of RenovoRx, Inc. (RNXT).
Where is RenovoRx, Inc. headquartered?
RenovoRx, Inc. (RNXT) is headquartered in Mountain View, CA, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.